IP Library Granted Patent US 11,627,920
Granted Patent B2
US 11,627,920 · App. 17/203,532 · Granted Apr 18, 2023

Method and apparatus for emission guided radiation therapy

Inventor: Samuel Mazin (Lafayette, CA)
Assignee: RefleXion Medical, Inc.
A61B6/037A61B6/0407A61B6/469A61B6/54A61B6/541A61N5/1067A61N5/1081G01T1/2978G01T1/2985A61N2005/109A61N2005/1052A61N2005/1072A61N2005/1074A61N2005/1087A61N2005/1089A61N2005/1091
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,627,920
App. No.
17/203,532
Granted
Apr 18, 2023
Kind
B2
Abstract

An apparatus comprising a radiation source, coincident positron omission detectors configured to detect coincident positron annihilation emissions originating within a coordinate system, and a controller coupled to the radiation source and the coincident positron emission detectors, the controller configured to identify coincident positron annihilation emission paths intersecting one or more volumes in the coordinate system and align the radiation source along an identified coincident positron annihilation emission path.

Claims (19)

1. A method of delivering radiation to living tumor tissue comprising:

detecting positron annihilation emission paths originating from a tumor that has taken up a PET radiotracer; and

directing radiation from a radiation source mounted on a rotatable gantry to the tumor based on the detected positron annihilation emission paths, wherein directing radiation comprises adjusting a configuration of a collimation assembly that is disposed in a radiation path of the radiation source while rotating the gantry.

2. The method of claim 1 , wherein the PET radiotracer comprises a positron-emitting radionuclide selected from the group consisting of fluorine-18, carbon-11, oxygen-15, and nitrogen-13.

3. The method of claim 2 , wherein the PET radiotracer is a metabolic PET radiotracer.

4. The method of claim 3 , wherein the metabolic PET tracer comprises fluorodeoxyglucose (FDG).

5. The method of claim 1 , wherein the rotatable gantry is a circular gantry.

6. The method of claim 1 , wherein directing radiation to the tumor occurs before the tumor moves substantially.

7. The method of claim 1 , further comprising constructing a map of positron annihilation emission path activity from the detected positron annihilation emission paths, and wherein directing radiation from the radiation source to the tumor is based on the map of positron annihilation emission path activity.

8. The method of claim 1 , further comprising constructing a map of positron annihilation emission path activity from a previous radiotherapy session, and wherein directing radiation from the radiation source to the tumor is based on the map of positron annihilation emission path activity.

9. The method of claim 1 , further comprising constructing an image of metabolic activity of the tumor based on a map of positron annihilation emission path activity constructed from the detected positron annihilation emission paths.

10. The method of claim 1 , wherein the tumor is located on a table and the method further comprises translating the table in steps and directing radiation to the tumor at each table step.

11. The method of claim 1 , further comprising generating an image of the tumor based on an accumulation of the detected positron annihilation emission paths.

12. The method of claim 11 , wherein the generated image is an image of metabolic activity of the tumor.

13. The method of claim 1 , further comprising using the generated image to modify a subsequent treatment.

14. The method of claim 1 , further comprising identifying the tumor by mapping activity of positron annihilation events.

15. The method of claim 1 , wherein the radiation source is selected from the group consisting of a high energy photon source, a particle source, a high energy electron source, a proton beam source, a neutron beam source, and a heavy ion beam source.

16. The method of claim 1 , wherein the radiation source comprises a radioactive isotope.

17. The method of claim 15 , wherein the radioactive isotope is an iridium isotope or a cobalt-60 isotope.

Assignments (2)
SECURITY INTEREST Recorded Jul 11, 2022
From: REFLEXION MEDICAL, INC.
To: OXFORD FINANCE LLC
Reel/Frame 060619/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2021
From: MAZIN, SAMUEL
To: REFLEXION MEDICAL, INC.
Reel/Frame 055625/0733 →
Continuity (9)
Continuation 16425416 · May 29, 2019
Continuation 15807383 · Nov 8, 2017
Continuation 14951194 · Nov 24, 2015
Continuation 14278973 · May 15, 2014
Continuation 13895255 · May 15, 2013
Continuation 13209275 · Aug 12, 2011
Continuation 12367679 · Feb 9, 2009
Provisional Application 61036709 · Mar 14, 2008
Related Publication 20210196212A1 · Jul 1, 2021
Cited By (8)
US 12,214,219 US 12,233,286 US 12,251,579 US 12,337,196 US 12,502,554 US 12,551,725 US 12,582,845 US 12,654,035